{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:51:57Z","timestamp":1777553517593,"version":"3.51.4"},"reference-count":27,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Objectives: To determine whether a Sabin strain inactivated poliovirus booster (sIPV) given concomitantly (same day, different sites) with MMRV or inactivated hepatitis A vaccine (HepA) is non-inferior in immunogenicity and comparable in safety to separate administration at the 18-month visit. Methods: Open-label, randomized Phase IV trial in healthy children (18~22 months), allocated 2:2:2:1:1 to sIPV&amp;MMRV, sIPV&amp;HepA, sIPV-only, MMRV-only, or HepA-only. Primary endpoints were Day-30 seroconversion rates (SCRs) for poliovirus types 1\u20133 (sIPV arms) and for HepA (HepA arms). Results: Of 892 screened, 889 were randomized; baseline characteristics were balanced. By Day 30, seroprotection was 100% for PV types 1\u20133 in all sIPV-containing arms. SCRs were high and similar across concomitant vs. separate administration; all pairwise SCR differences met non-inferiority (\u221210% margin). Adjusted post-vaccination GMTs were comparable across serotypes. For HepA, Day-30 SPoR was 99.3% vs. 100.0%, and adjusted GMC was 412.2 vs. 465.9 (p = 0.2224). For MMRV, Day-30 SPoR was 100% in both groups with similar adjusted GMCs. Within 30 days, overall adverse reactions were 14.5%\/17.4%\/16.3%\/7.3%\/10.8% (sIPV&amp;MMRV\/sIPV&amp;HepA\/sIPV-only\/MMRV-only\/HepA-only), mostly mild to moderate; no vaccine-related SAEs (NCT06442449). Conclusions: Same-day sIPV co-administration with MMRV or HepA was non-inferior and well tolerated, supporting programmatic adoption.<\/jats:p>","DOI":"10.3390\/vaccines13111087","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:47:36Z","timestamp":1761266856000},"page":"1087","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunogenicity and Safety of Sabin Strain Inactivated Poliovirus Vaccine Booster Dose Administered Separately or Concomitantly with Inactivated Hepatitis A Vaccine or Measles\u2013Mumps\u2013Rubella Combined Attenuated Live Vaccine: An Open-Labelled, Randomized, Controlled, Phase 4 Clinical Trial"],"prefix":"10.3390","volume":"13","author":[{"given":"Jialei","family":"Hu","sequence":"first","affiliation":[{"name":"Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine), Nanjing 210009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7804-3786","authenticated-orcid":false,"given":"Weixiao","family":"Han","sequence":"additional","affiliation":[{"name":"Sinovac Holding Group Co., Ltd., Beijing 100085, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Chu","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine), Nanjing 210009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengzhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sinovac Holding Group Co., Ltd., Beijing 100085, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Tuo","sequence":"additional","affiliation":[{"name":"Sinovac Holding Group Co., Ltd., Beijing 100085, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqian","family":"Duan","sequence":"additional","affiliation":[{"name":"Sinovac Holding Group Co., Ltd., Beijing 100085, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8284-1642","authenticated-orcid":false,"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Sinovac Holding Group Co., Ltd., Beijing 100085, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Sinovac Holding Group Co., Ltd., Beijing 100085, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunfang","family":"Luan","sequence":"additional","affiliation":[{"name":"Sinovac Holding Group Co., Ltd., Beijing 100085, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxing","family":"Pan","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine), Nanjing 210009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Jiao","sequence":"additional","affiliation":[{"name":"Sinovac Holding Group Co., Ltd., Beijing 100085, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"ref_1","unstructured":"Global Polio Eradication Initiative (GPEI) (2025, September 25). Factsheet (1 April 2025). Available online: https:\/\/polioeradication.org\/wp-content\/uploads\/2025\/04\/GPEI-general-factsheet-20250401.pdf."},{"key":"ref_2","unstructured":"Initiative for Vaccine Research, and Executive Agency (IDEA) (2025, September 25). Current Status of Global Polio Eradication\u2014June 2025. Available online: https:\/\/id-ea.org\/current-status-of-global-polio-eradication-june-2025\/."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Bricks, L.F., Macina, D., and Vargas-Zambrano, J.C. (2024). Polio Epidemiology: Strategies and Challenges for Polio Eradication Post the COVID-19 Pandemic. Vaccines, 12.","DOI":"10.3390\/vaccines12121323"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.15585\/mmwr.mm7319a4","article-title":"Progress Toward Poliomyelitis Eradication\u2014Worldwide, January 2022\u2013December 2023","volume":"73","author":"Geiger","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_5","unstructured":"World Health Organization (2025, September 25). Poliovirus Containment: Guidance to Minimize Risks for Facilities Collecting, Handling or Storing Materials Potentially Infec-tious for Polioviruses. Second Edition. Web Annex A: Country- and Area-Specific Poliovirus Data, June 2024 Update (WHO\/POLIO\/24.02). Available online: https:\/\/iris.who.int\/handle\/10665\/380037."},{"key":"ref_6","unstructured":"World Health Organization (2025, September 25). Global Polio Eradication Initiative: Annual Report 2023. Available online: https:\/\/iris.who.int\/handle\/10665\/379270."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"909","DOI":"10.15585\/mmwr.mm7341a1","article-title":"Update on Vaccine-Derived Poliovirus Outbreaks\u2014Worldwide, January 2023\u2013June 2024","volume":"73","author":"Greene","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_8","unstructured":"World Health Organization (on Behalf of GPEI) (2025, September 25). Polio Eradication Strategy 2022\u20132026. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/341938\/9789240024830-eng.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/infdis\/jiw550","article-title":"A Supply and Demand Management Perspective on the Accelerated Global Introductions of Inactivated Poliovirus Vaccine in a Constrained Supply Market","volume":"216","author":"Lewis","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_10","unstructured":"UNICEF Supply Division (2025, September 25). Inactivated Polio Vaccine: Supply and Demand Update. Available online: https:\/\/www.unicef.org\/supply\/media\/23146\/file\/IPV-Market%20Note-February-2025.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.biologicals.2006.02.011","article-title":"Technology Transfer of Sabin-IPV to New Developing Country Markets","volume":"34","author":"Kreeftenberg","year":"2006","journal-title":"Biologicals"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/infdis\/jiy736","article-title":"Immunogenicity and Safety of a Sabin Strain-Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial","volume":"220","author":"Hu","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"ofz380","DOI":"10.1093\/ofid\/ofz380","article-title":"Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared with Salk Strain Inactivated Poliovirus Vaccine in Different Sequential Schedules with Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China","volume":"6","author":"Hu","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"126183","DOI":"10.1016\/j.vaccine.2024.126183","article-title":"Safety and 6-Month Immune Persistence of Inactivated Poliovirus Vaccine (Sabin Strains) Simultaneously Administered with Other Vaccines for Primary and Booster Immunization in Jiangxi Province, China","volume":"42","author":"Guo","year":"2024","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"127448","DOI":"10.1016\/j.vaccine.2025.127448","article-title":"Immunogenicity and Safety of Sequential Sabin Strain Inactivated Poliovirus Vaccine from Different Manufacturers in Infants: Randomized, Blinded, Controlled Trial","volume":"61","author":"Wang","year":"2025","journal-title":"Vaccine"},{"key":"ref_16","unstructured":"World Health Organization (2022). Polio vaccines: WHO position paper\u2014June 2022. Wkly. Epidemiol. Record., 97, 277\u2013300."},{"key":"ref_17","unstructured":"World Health Organization (2017). Measles vaccines: WHO position paper\u2014April 2017. Wkly. Epidemiol. Record., 92, 205\u2013228."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Xu, J., Liu, Y., Qiu, W., Li, W., Hu, X., Li, X., Fan, Q., Tang, W., Wang, Y., and Wang, Q. (2024). Immunogenicity Evaluation of Primary Polio Vaccination Schedule with Inactivated Poliovirus Vaccines and Bivalent Oral Poliovirus Vaccine. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09389-8"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e250234","DOI":"10.3201\/eid3110.250234","article-title":"Detection of Immunity Gap before Measles Outbreak, Ho Chi Minh City, Vietnam, 2024","volume":"31","author":"Ong","year":"2025","journal-title":"Emerg. Infect. Dis."},{"key":"ref_20","unstructured":"World Health Organization (2022). Hepatitis A Vaccines: WHO Position Paper\u2014October 2022. Wkly. Epidemiol. Rec., 97, 493\u2013512."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Yan, R., He, H., Deng, X., Zhou, Y., Tang, X., Zhu, Y., Liang, H., Chen, Y., Yang, M., and Du, Y. (2024). A Serological Survey of Measles and Rubella Antibodies among Different Age Groups in Eastern China. Vaccines, 12.","DOI":"10.3390\/vaccines12080842"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1080\/21645515.2021.1924522","article-title":"One Single-Center Serological Survey on Measles, Rubella and Mumps Antibody Levels of People in Youyang, China","volume":"17","author":"Wang","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijid.2023.10.006","article-title":"Immunogenicity and Safety of Concomitant Administration of the Sabin-Strain-Based Inactivated Poliovirus Vaccine, the Diphtheria-Tetanus-Acellular Pertussis Vaccine, and Measles-Mumps-Rubella Vaccine to Healthy Infants Aged 18 Months in China","volume":"137","author":"Xu","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.vaccine.2011.10.065","article-title":"An Open-Label, Randomized, Multi-Center Study of the Immunogenicity and Safety of DTaP-IPV (Kinrix\u2122) Co-Administered with MMR Vaccine with or without Varicella Vaccine in Healthy Pre-School Age Children","volume":"30","author":"Klein","year":"2012","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S2214-109X(16)30075-4","article-title":"Safety and Immunogenicity of Inactivated Poliovirus Vaccine When Given with Measles-Rubella Combined Vaccine and Yellow Fever Vaccine and When Given via Different Administration Routes: A Phase 4, Randomised, Non-Inferiority Trial in The Gambia","volume":"4","author":"Clarke","year":"2016","journal-title":"Lancet Glob. Health"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.vaccine.2023.02.073","article-title":"Safety of Concomitant Administration of Inactivated Hepatitis A Vaccine with Other Vaccines in Children under 16 Years Old in Post-Marketing Surveillance","volume":"41","author":"Wu","year":"2023","journal-title":"Vaccine"},{"key":"ref_27","unstructured":"World Health Organization (2025, September 25). Multiple Injections: Acceptability and Safety. Available online: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/essential-programme-on-immunization\/implementation\/multiple-injections."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/11\/1087\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T01:12:36Z","timestamp":1761268356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/11\/1087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["vaccines13111087"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13111087","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}